Fibrosis (chronic scarring) accounts for up to 45% of deaths in the developed world, but there are no FDA-approved anti-fibrotic therapies. Researchers at Nationwide Children's have found that exosomes from healthy cells contain molecular signals reflective of a healthy state and can be delivered to fibrotic cells and mitigate or reverse fibrosis. This novel therapy will have an impact on numerous diseases, including liver disease, cardiovascular disease, pulmonary fibrosis, kidney disease, and macular degeneration.